On July 24, 2025, Dare Bioscience, Inc. confirmed compliance with Nasdaq's stockholders' equity requirement, ensuring it meets listing standards but will undergo a one-year review period with a Mandatory Panel Monitor. If non-compliance occurs during this time, Nasdaq will review and could initiate a delisting process.